High-affinity immunoglobulin epsilon receptor (Fc-epsilon-RI) (FcεRI)

The high-affinity immunoglobulin epsilon receptor (Fc-epsilon-RI) is a key mediator of allergic reactions, primarily expressed on mast cells and basophils (UniProt P12319). It functions by binding the Fc portion of IgE antibodies; when these antibodies encounter specific allergens, such as ragweed pollen (Ambrosia artemisiifolia), the receptors are cross-linked, triggering the release of inflammatory mediators like histamine (StatPearls, NBK513315). This signaling cascade is the fundamental mechanism of Type I hypersensitivity and allergic diseases, including allergic rhinitis and asthma (NCBI Gene ID 2205). Therapeutic strategies often involve monoclonal antibodies like omalizumab, which bind to circulating IgE to prevent its interaction with Fc-epsilon-RI (DrugBank DB00043). Additionally, allergen-specific immunotherapy (AIT) uses ragweed extracts to induce immune tolerance and reduce the sensitivity of this pathway over time. By targeting the IgE/Fc-epsilon-RI axis, clinicians can manage symptoms of seasonal allergies and prevent severe systemic reactions in sensitized patients.

Other names

FCER1High affinity IgE receptorFc epsilon RIIgE receptorFCER1A

Monoclonal antibodies like omalizumab bind to free IgE, preventing its interaction with the Fc-epsilon-RI receptor, thereby inhibiting mast cell and basophil activation. Allergen immunotherapy involves controlled exposure to allergens to induce immune tolerance and shift the immune response from IgE-mediated to IgG4-mediated (DrugBank DB00043).